Mahshid Panahi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mahshid Panahi has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Hadi Karbalaie Niya
Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
2 shared publications - Ahmad Tavakoli
Biological Products and Blood Safety Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
1 shared publication - Ali Salimi Jeda
Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Alireza Tabibzadeh
Rajaei Clinical Research Development Unit (CRDU) of Shahid Rajaei Hospital, Alborz University of Medical Sciences, Karaj, Iran
1 shared publication Arezoo Marjani
Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication- Atiyeh Dabouian
Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 16 December 2023
- Published by Brieflands in International Journal of Cancer Management
- Vol. 16 (1)
Molecular Investigation of Occult Hepatitis B Virus Infection Among Patients with Liver Cancers
Background: Hepatitis B virus (HBV) is still the leading cause of hepatocellular carcinoma (HCC). HBV could persist in the low replicate state that is defines as occult hepatitis B virus infection (OBI). Recently, OBI has been defined important in the development and/or exacerbation of HCC and other liver diseases. Objectives: This study tried to determine the frequency of OBI among liver tumor samples. Methods: This cross-sectional study was performed among patients with HCC and intrahepatic cholangiocarcinoma (iCCA) in hospitals affiliated with Iran University of Medical Sciences. Liver tumor samples (Fresh frozen and formalin fixed paraffin embedded) were processed for isolation of DNA and then subjected to molecular assays, including PCR examinations of HBV genes (S, X, and C), determination of viral loads, detection of HBV-cccDNA, phylogenetic analysis, and assessment of mutations in HBsAg and RT regions. Results: In total, there were 93 participants, including HCC (n = 60), iCCA (n = 33); among which, 15% were detected positive for OBI. The OBI among HCC and iCCA were 18.3% and 9.1%, respectively. The mean intrahepatic viral load was 1.3 × 105 ± 1.4 × 102 copies/µl, and 5 had detectable cccDNA. The OBI subjects belonged to the HBV genotype D and subgenotype D1. In the HBsAg protein, T45N (33.3%) and P105A (25%) were the most prevalent mutations. N53K (33.3%), Y54H (25%), L80I (33.3%), and A113G (25%) were missense mutations that were observed in the RT domain. Conclusions: HBV-DNA was detected among liver tumor samples with negative HBsAg status. The results of viral load and cccDNA tests are important in identification and prognosis of liver diseases. It’s needed more precise molecular and cohort studies to clarify the functions of OBI in liver diseases.
- 16 December 2023
- Published by Brieflands in International Journal of Cancer Management
- Vol. 16 (1)
Open AccessMolecular Investigation of Occult Hepatitis B Virus Infection Among Patients with Liver Cancers
Background: Hepatitis B virus (HBV) is still the leading cause of hepatocellular carcinoma (HCC). HBV could persist in the low replicate state that is defines as occult hepatitis B virus infection (OBI). Recently, OBI has been defined important in the development and/or exacerbation of HCC and other liver diseases. Objectives: This study tried to determine the frequency of OBI among liver tumor samples. Methods: This cross-sectional study was performed among patients with HCC and intrahepatic cholangiocarcinoma (iCCA) in hospitals affiliated with Iran University of Medical Sciences. Liver tumor samples (Fresh frozen and formalin fixed paraffin embedded) were processed for isolation of DNA and then subjected to molecular assays, including PCR examinations of HBV genes (S, X, and C), determination of viral loads, detection of HBV-cccDNA, phylogenetic analysis, and assessment of mutations in HBsAg and RT regions. Results: In total, there were 93 participants, including HCC (n = 60), iCCA (n = 33); among which, 15% were detected positive for OBI. The OBI among HCC and iCCA were 18.3% and 9.1%, respectively. The mean intrahepatic viral load was 1.3 × 105 ± 1.4 × 102 copies/µl, and 5 had detectable cccDNA. The OBI subjects belonged to the HBV genotype D and subgenotype D1. In the HBsAg protein, T45N (33.3%) and P105A (25%) were the most prevalent mutations. N53K (33.3%), Y54H (25%), L80I (33.3%), and A113G (25%) were missense mutations that were observed in the RT domain. Conclusions: HBV-DNA was detected among liver tumor samples with negative HBsAg status. The results of viral load and cccDNA tests are important in identification and prognosis of liver diseases. It’s needed more precise molecular and cohort studies to clarify the functions of OBI in liver diseases.
- Open Access
- 20 July 2020
- Published by Brieflands in International Journal of Cancer Management
- Vol. 13 (7)
The Molecular Epidemiology of Herpes Simplex Virus Type 1 and 2 (HSV-1 and HSV-2) in Head and Neck Cancer (HNC)
Background: Head and neck cancers (HNC) constitute the sixth common type of malignancies worldwide and can affect a wide range of anatomical regions. The role of the herpes simplex virus (HSV) in oral squamous cell carcinoma (OSCC) has been previously investigated. Objectives: The objective of the current study was to evaluate the molecular epidemiology of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) in patients with HNC. Methods: A total of 156 patients with HNC were chosen including 90 biopsies and 66 formalin-fixed paraffin-embedded (FFPE) samples. HNC was confirmed and affected different anatomical regions. HSV detection was performed by a polymerase chain reaction (PCR) and HSV typing was assessed by a multiplex PCR. Results: The 156 HNC specimens included 35 (22.4%) larynx, 29 (18.6%) tongue, 6 (3.8%) glands (parotid and tonsil), 12 (7.6%) nasopharynx, 9 (5.7%) pharynx, 33 (21%) vocal cord, 3 (1.9%) palatine, glottis 17 (10.8%), nasal 2 (1.3%), mandibular 4 (2.5%), lip 4 (2.5%), neck 1 (0.6%), and face 1 (0.6%). The mean ± SD of the patients’ age was 60.3 ± 12.65, where 121 (77.1%) were male. The HSV was detected in 4 (2.6%) samples and 75% of HSV positive samples were HSV-1. Conclusions: The rate of HSV infection in Iranian patients with HNC was 2.6% with the majority being HSV-1 (75%). As a preliminary study in Iranian patients with HNC, cancer location was not statistically significant. Further investigations are needed to assess the role of HSV in HNC.
- 20 July 2020
- Published by Brieflands in International Journal of Cancer Management
- Vol. 13 (7)
Open AccessThe Molecular Epidemiology of Herpes Simplex Virus Type 1 and 2 (HSV-1 and HSV-2) in Head and Neck Cancer (HNC)
Background: Head and neck cancers (HNC) constitute the sixth common type of malignancies worldwide and can affect a wide range of anatomical regions. The role of the herpes simplex virus (HSV) in oral squamous cell carcinoma (OSCC) has been previously investigated. Objectives: The objective of the current study was to evaluate the molecular epidemiology of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) in patients with HNC. Methods: A total of 156 patients with HNC were chosen including 90 biopsies and 66 formalin-fixed paraffin-embedded (FFPE) samples. HNC was confirmed and affected different anatomical regions. HSV detection was performed by a polymerase chain reaction (PCR) and HSV typing was assessed by a multiplex PCR. Results: The 156 HNC specimens included 35 (22.4%) larynx, 29 (18.6%) tongue, 6 (3.8%) glands (parotid and tonsil), 12 (7.6%) nasopharynx, 9 (5.7%) pharynx, 33 (21%) vocal cord, 3 (1.9%) palatine, glottis 17 (10.8%), nasal 2 (1.3%), mandibular 4 (2.5%), lip 4 (2.5%), neck 1 (0.6%), and face 1 (0.6%). The mean ± SD of the patients’ age was 60.3 ± 12.65, where 121 (77.1%) were male. The HSV was detected in 4 (2.6%) samples and 75% of HSV positive samples were HSV-1. Conclusions: The rate of HSV infection in Iranian patients with HNC was 2.6% with the majority being HSV-1 (75%). As a preliminary study in Iranian patients with HNC, cancer location was not statistically significant. Further investigations are needed to assess the role of HSV in HNC.
- 5 February 2020
- Published by Springer Nature in Pituitary
- Vol. 23 (3) , 232-245
Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics
Purpose The regulatory effects of estradiol on pituitary homeostasis have been well documented. However, the expression patterns of ERα66 and ERα36 and their correlations with the clinical course of postoperative prolactinoma tumors remain unclear. Methods The expression of ERα36, ERα66, Ki67, p53, and CD31 were determined by immunohistochemistry in 62 prolactinoma patients. Snap-frozen tumors and normal pituitaries were also examined by western blotting for estrogen receptor detection. Results A broad expression of ERα36 was identified in normal pituitaries. The median scores of ERα36 and ERα66 expression were 8 and 6 in normal pituitaries and 4 and 0 in tumors, respectively. Four phenotypes of ERα36 and ERα66 expression were explored in tumors with regard to sex, invasiveness, dopamine resistance, and recurrence. Low ERα36 expression was associated with tumor invasion and increased Ki67. Low ERα66 expression was associated with tumor invasion, dopamine-agonist resistance, and enhanced tumor size. Multivariable logistic regression analysis showed that low ERα36 expression is an independent risk factor for invasiveness. The significant inverse association of ERα66 with invasiveness, dopamine resistance, and tumor size remained significant after adjustment for sex as a potential confounder. After controlling for sex, the low ERα66/low ERα36 phenotype was 6.24 times more prevalent in invasive tumors than in noninvasive tumors. Although the decreasing trend of CD31 expression from surrounding nontumoral lactotroph adenomas to tumors was similar to that of the estrogen receptors, a significant correlation was not observed here. Conclusion The decreasing trends of ERα36 and ERα66 expression from normal pituitaries to tumors are associated with aggressive clinical behavior.
- 5 February 2020
- Published by Springer Nature in Pituitary
- Vol. 23 (3) , 232-245
Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics
Purpose The regulatory effects of estradiol on pituitary homeostasis have been well documented. However, the expression patterns of ERα66 and ERα36 and their correlations with the clinical course of postoperative prolactinoma tumors remain unclear. Methods The expression of ERα36, ERα66, Ki67, p53, and CD31 were determined by immunohistochemistry in 62 prolactinoma patients. Snap-frozen tumors and normal pituitaries were also examined by western blotting for estrogen receptor detection. Results A broad expression of ERα36 was identified in normal pituitaries. The median scores of ERα36 and ERα66 expression were 8 and 6 in normal pituitaries and 4 and 0 in tumors, respectively. Four phenotypes of ERα36 and ERα66 expression were explored in tumors with regard to sex, invasiveness, dopamine resistance, and recurrence. Low ERα36 expression was associated with tumor invasion and increased Ki67. Low ERα66 expression was associated with tumor invasion, dopamine-agonist resistance, and enhanced tumor size. Multivariable logistic regression analysis showed that low ERα36 expression is an independent risk factor for invasiveness. The significant inverse association of ERα66 with invasiveness, dopamine resistance, and tumor size remained significant after adjustment for sex as a potential confounder. After controlling for sex, the low ERα66/low ERα36 phenotype was 6.24 times more prevalent in invasive tumors than in noninvasive tumors. Although the decreasing trend of CD31 expression from surrounding nontumoral lactotroph adenomas to tumors was similar to that of the estrogen receptors, a significant correlation was not observed here. Conclusion The decreasing trends of ERα36 and ERα66 expression from normal pituitaries to tumors are associated with aggressive clinical behavior.
- Open Access
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 8543872
Xanthomicrol Exerts Antiangiogenic and Antitumor Effects in a Mouse Melanoma (B16F10) Allograft Model
Xanthomicrol, a trimethoxylated hydroxyflavone, is the main active component of Dracocephalum kotschyi Boiss leaf extract. Preliminary in vitro studies identified this compound as a potential antiangiogenic and anticancer agent. This study aimed to evaluate in vivo anticancer effect of xanthomicrol and investigate its molecular mechanism of action in a mouse melanoma (B16F10) model. Effect of xanthomicrol on B16F10 melanoma cell viability was determined using the MTT assay. For in vivo experiments, C57BL/6 mice were inoculated subcutaneously with B16F10 cells. After five days, once daily administration of xanthomicrol, thalidomide, or vehicle was commenced and continued for 21 consecutive days. On the 26th day, blood samples and tumor biopsies were taken for subsequent molecular analysis. Xanthomicrol showed inhibitory effect on viability of B16F10 melanoma cells (IC50 value: 3.433 μg/ml). Initial tumor growth, tumor volume and weight, and angiogenesis were significantly decreased in xanthomicrol‐treated animals compared with those in vehicle group. Protein expression of phosphorylated Akt, mRNA expressions of HIF‐1α and VEGF in tumor tissues, and serum VEGF were significantly decreased in xanthomicrol‐treated animals compared with vehicle‐treated animals. Thus, xanthomicrol inhibited cancer cell growth both in vitro and in vivo. This effect, at least in part, was exerted by interfering with PI3K/Akt signaling pathway and inhibiting VEGF secretion by tumor cells. Further studies are required to elucidate the exact molecular mechanisms of antitumor activity of xanthomicrol.
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 8543872
Open AccessXanthomicrol Exerts Antiangiogenic and Antitumor Effects in a Mouse Melanoma (B16F10) Allograft Model
Xanthomicrol, a trimethoxylated hydroxyflavone, is the main active component of Dracocephalum kotschyi Boiss leaf extract. Preliminary in vitro studies identified this compound as a potential antiangiogenic and anticancer agent. This study aimed to evaluate in vivo anticancer effect of xanthomicrol and investigate its molecular mechanism of action in a mouse melanoma (B16F10) model. Effect of xanthomicrol on B16F10 melanoma cell viability was determined using the MTT assay. For in vivo experiments, C57BL/6 mice were inoculated subcutaneously with B16F10 cells. After five days, once daily administration of xanthomicrol, thalidomide, or vehicle was commenced and continued for 21 consecutive days. On the 26th day, blood samples and tumor biopsies were taken for subsequent molecular analysis. Xanthomicrol showed inhibitory effect on viability of B16F10 melanoma cells (IC50 value: 3.433 μg/ml). Initial tumor growth, tumor volume and weight, and angiogenesis were significantly decreased in xanthomicrol‐treated animals compared with those in vehicle group. Protein expression of phosphorylated Akt, mRNA expressions of HIF‐1α and VEGF in tumor tissues, and serum VEGF were significantly decreased in xanthomicrol‐treated animals compared with vehicle‐treated animals. Thus, xanthomicrol inhibited cancer cell growth both in vitro and in vivo. This effect, at least in part, was exerted by interfering with PI3K/Akt signaling pathway and inhibiting VEGF secretion by tumor cells. Further studies are required to elucidate the exact molecular mechanisms of antitumor activity of xanthomicrol.